Alpha Cognition receives USPTO patent for ALPHA-1062 traumatic brain injury treatment method

Vancouver-based Alpha Cognition Inc., (NASDAQ: ACOG), a biopharmaceutical company focused on neurodegenerative disorder therapy, received US Patent No. 12,589,099 from the USPTO, covering methods of treating both confirmed and suspected traumatic brain injury (TBI) using ALPHA-1062. The grant extends protection through 2045 and formalizes the company’s entry into TBI as a distinct indication from its existing Alzheimer’s disease franchise. This method-of-use patent is relevant because it covers a cholinergic modulation approach in a CNS indication where no approved pharmacological therapies currently exist.

ALPHA-1062 is a prodrug formulation of galantamine, a compound that functions as an acetylcholinesterase inhibitor and a modulator of neuronal nicotinic receptors, particularly the alpha-7 subtype. In TBI, cholinergic deficits arise from diffuse axonal injury and disruption of basal forebrain projections, making acetylcholinesterase inhibition a mechanistically relevant strategy for addressing post-injury cognitive impairment. The prodrug design is intended to improve the tolerability and delivery profile relative to standard galantamine formulations. The patent’s inclusion of suspected TBI cases, in addition to confirmed diagnoses, extends the potential clinical scope to acute care and emergency settings.

Alpha Cognition is also developing ALPHA-1062 as an intranasal formulation for cognitive impairment associated with mild TBI, and in combination with memantine for moderate to severe Alzheimer’s dementia. No human efficacy data for ALPHA-1062 in TBI were identified in the reviewed public sources. Zunveyl (benzgalantamine), the company’s approved acetylcholinesterase inhibitor for Alzheimer’s disease, shares IP infrastructure with ALPHA-1062, and the Alpha Cognition patent issued for TBI is described as complementing that existing portfolio.

Context and competitive landscape

The TBI therapeutic landscape remains structurally distinct from neurodegenerative indications such as Alzheimer’s disease. No pharmacological therapy has received approval from the US FDA specifically for TBI as a primary indication, leaving a fragmented environment of acute-care interventions and off-label symptomatic management. This absence of approved agents defines the commercial and regulatory backdrop for Alpha Cognition’s ALPHA-1062 program.

Development activity in TBI spans multiple mechanistic approaches, reflecting the heterogeneity of the condition. Programs targeting acute injury pathways include glibenclamide (BIIB093), developed by Biogen, which acts on the SUR1-TRPM4 channel and has been studied in severe TBI-associated cerebral edema. These approaches are primarily aimed at reducing early mortality and structural damage rather than addressing longer-term cognitive sequelae.

In contrast, a separate group of programs is focused on post-injury cognitive impairment, which is the segment most relevant to cholinergic strategies. These include neurosteroid-based and neuropeptide-based candidates such as PRV-002 (originally developed by Prevacus and subsequently acquired) and OXE-103 from Oxeia Biopharmaceuticals. Publicly available information on clinical progress and efficacy for these agents remains limited or primarily derived from company disclosures, underscoring the early-stage and heterogeneous nature of the field.

Established acetylcholinesterase inhibitors—including donepezil (marketed as Aricept by Eisai and Pfizer) and rivastigmine (Exelon, from Novartis)—have been explored in investigator-initiated or off-label settings for TBI-related cognitive symptoms. However, none carry an approved indication in TBI, and their use in this context remains non-standardized.

Against this backdrop, ALPHA-1062 occupies a position within the cholinergic modulation segment, differentiated primarily by its prodrug design and associated intellectual property. While the underlying pharmacological class is well established, Alpha Cognition’s patent covering a specific formulation and method of use in TBI may provide a degree of exclusivity not available to legacy acetylcholinesterase inhibitors, which are largely off-patent.